Literature DB >> 1513579

Treatment of postcataract fibrinous membranes with tissue plasminogen activator.

J Moon1, S Chung, Y Myong, S Chung, C Park, N Baek, S Rhee.   

Abstract

PURPOSE: The purpose of this study is to investigate the efficacy and toxicity of tissue plasminogen activator (tPA) in treatment of postcataract fibrinous membranes.
METHODS: The authors injected 25 micrograms of tPA into the anterior chamber of 52 pseudophakic eyes with moderate to severe fibrinous membranes that developed after cataract surgery.
RESULTS: Intraocular tPA injection resulted in complete fibrinolysis in 47 of 52 eyes (90%) and partial fibrinolysis in 5 of 52 eyes (10%). In cases of complete fibrinolysis, resolution of the fibrinous membrane occurred within 30 minutes in 22 of 47 eyes (47%) and within 1 hour in 25 of 47 eyes (53%). No evidence of toxicity was observed as measured by slit-lamp biomicroscopy, intraocular pressure, and corneal endothelial cell density, size, and morphology. Complications of tPA administration included periorbital pain (4 eyes), anterior chamber hemorrhage (4 eyes), and anterior chamber turbidity (3 eyes).
CONCLUSION: The authors believe that intraocular tPA is effective and safe in the treatment of postcataract fibrinous membranes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1513579     DOI: 10.1016/s0161-6420(92)31815-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

1.  Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study.

Authors:  A Glacet-Bernard; D Kuhn; A K Vine; H Oubraham; G Coscas; G Soubrane
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

Review 2.  Factors affecting the efficacy of antibiotics in the treatment of experimental postoperative endophthalmitis.

Authors:  G A Stern
Journal:  Trans Am Ophthalmol Soc       Date:  1993

3.  LMWH inhibits anterior chamber inflammation after extra capsular lens extraction through down regulation of bFGF content in aqueous humor.

Authors:  Jian-Ming Wang; Lei Xiong; Quan-Chen Xiong; Ya-Zhi Fan
Journal:  Int J Ophthalmol       Date:  2012-08-18       Impact factor: 1.779

4.  Recombinant tissue plasminogen activator following paediatric cataract surgery.

Authors:  J S Mehta; G G Adams
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

5.  Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery.

Authors:  H Siatiri; A H Beheshtnezhad; H Asghari; N Siatiri; S Moghimi; N Piri
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

6.  Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study.

Authors:  A Heiligenhaus; B Steinmetz; R Lapuente; P Krallmann; C Althaus; W K Steinkamp; B Dick
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

7.  Intraocular Lens Opacification following Intracameral Injection of Recombinant Tissue Plasminogen Activator to Treat Inflammatory Membranes after Cataract Surgery.

Authors:  Simon S M Fung; Evripidis Sykakis; Niaz M Islam; Hadi J Zambarakji; Ramin Khoramnia; Gerd U Auffarth; Dipak N Parmar
Journal:  J Ophthalmol       Date:  2015-03-18       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.